IP Library Granted Patent US 6,906,183
Granted Patent B2
US 6,906,183 · App. 09/459,908 · Granted Jun 14, 2005

Process for the separation of glycosylated and nonglycosylated proteins

Assignee: Delta Biotechnology Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,906,183
App. No.
09/459,908
Granted
Jun 14, 2005
Kind
B2
Abstract

A process for the partial or complete separation of glycosylated and nonglycosylated proteins is described, in which: a) a triazine dye immobilized on a matrix is incubated with a mixture of glycosylated and nonglycosylated proteins, b) the matrix is then washed to remove the unbound proteins, and c) the proteins are eluted by means of a stepwise or continuous increase in the ionic strength or in the pH, nonglycosylated proteins and proteins having an increasing degree of glycosylation being collected separately from one another in the eluate fractions obtained. By means of the use of this process it is possible, for example, to prepare a human albumin which is free of glycoside bonds and is expressed in yeast cells.

Claims (15)

1. A process for the partial or complete separation of a mixture of glycosylated and nonglycosylated variants of a protein, wherein the glycosylated variants bear mannose, which comprises

a) incubating a triazine dye immobilized on a matrix with the mixture of glycosylated and nonglycosylated variants,

b) washing the matrix with a buffer to remove the unbound variants,

c) eluting the variants from the matrix by means of a stepwise or continuous increase in the ionic strength or in the pH of the buffer, and

d) collecting nonglycosylated variants and variants having an increasing degree of glycosylation separately from one another in the eluate fractions obtained.

2. The process of claim 1 , wherein the matrix consists of agarose, crosslinked or noncrosslinked dextran, polyacrylamide or cellulose.

3. The process of claim 1 , wherein one or more compounds from the group consisting of Reactive Green 5, Reactive Blue 2, and Reactive Yellow 3 are employed as triazine dyes.

4. The process of claim 1 , wherein the mixture of glycosylated and nonglycosylated variants is incubated with the triazine dye matrix at a pH of between 3.5 and 10.

5. The process of claim 1 , wherein the nonglycosylated variants have been separated from glycosylated variants.

6. The process of claim 5 , wherein the glycosylated and nonglycosylated variants have been prepared recombinantly in eukaryotic cells or in transgenic microorganisms.

7. The process of claim 5 , wherein the protein is human albumin expressed in yeast cells.

8. The process of claim 6 , wherein the eukaryotic cells are yeast cells.

9. The process of claim 3 , wherein the mixture of glycosylated and nonglycosylated variants is incubated with Reactive Green 5 at a pH of between 6and 10.

10. The process of claim 3 , wherein the mixture of glycosylated and nonglycosylated variants is incubated with Reactive Yellow 3 at a pH of between 3.5 and 6.5.

11. The process of claim 3 , wherein the mixture of glycosylated and nonglycosylated variants is incubated with Reactive Blue 2.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2011
From: NOVOZYMES BIOPHARMA UK LIMITED
To: NOVOZYMES BIOPHARMA DK A/S
Reel/Frame 026813/0938 →
CHANGE OF NAME Recorded Aug 25, 2011
From: DELTA BIOTECHNOLOGY LIMITED
To: NOVOZYMES BIOPHARMA UK LIMITED
Reel/Frame 026808/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2005
From: AVENTIS BEHRING GMBH
To: DELTA BIOTECHNOLOGY LTD.
Reel/Frame 016070/0703 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2000
From: CENTEON PHARMA GMBH
To: AVENTIS BEHRING GMBH
Reel/Frame 010814/0231 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 1999
From: ROMISCH, JURGEN; WEISSE, JORG; STAUSS, HARALD; FEUSSNER, ANNETTE
To: CENTEON PHARMA GMBH
Reel/Frame 010459/0804 →
Priority Claims (1)
DE 198 58 777 · Dec 18, 1998 · national
Continuity (1)
Related Publication 20020165367A1 · Nov 7, 2002